Representing and supporting medical oncologists in the UK

Interventional Oncology Workshop & ACP Trainees Weekend 2021

There is no charge for ACP/ BSIR/ IOUK members to attend.

Interventional Oncology Workshop 
Friday 15 October 2021

Organised in conjunction with:

 

 

A workshop on Friday 15 October on Interventional Oncology is a joint interdisciplinary venture between the ACP and the British Society of Interventional Radiology (BSIR), to highlight some of the new advances in the rapidly expanding field of Interventional Oncology.  In addition to lectures by experts, there will be site specific MDTs with interactive discussions about patients’ cancer care.  We hope you will find the event highly relevant to current clinical practice in cancer management.

Venue: Mercure Bristol Grand Hotel

Speakers: Click here to download details.

Programme: Click here to download the programme.

 

Programme

Friday 15 October 2021

0830 Registration with tea & coffee  
0900  Welcome and introduction - Tze Min Wah  
0910 Introduction for The Ken Bagshawe Lecture - Alison Young
Session 1
The Ken Bagshawe Lecture:
Interventional Oncology- 4th pillar of cancer care and its role with Immuno-oncology 
Afshin Gangi
 
1000 Session 2
MDT: Renal Cancer - Chair: Guy Hickson
Case presentation: Alistair McLaren and Amy Greenwood
Expert Panel: Philip Haslam, Vincent Khoo, Sean O’Cathail, Nicholas Railton, Maxine Tran
 
1100 TEA & COFFEE  
1130 Session 3
MDT: Treatment of Oligometastatic Disease/Lung/Bone - Chair: Sean O’Cathail Case presentation: Sonam Ansel and Andrew Viggars
Expert panel: Steve Bandula, Nimit Goyal, Peter Kennedy, Rebecca Muirhead, Christian Ottensmeier
 
1230 LUNCH  
1345 Introduction for The Robert Bardsley Lecture - Philip Haslam, Vice President BSIR
The Robert Bardsley Lecture:
Stereotactic Body Radiation Therapy- the time is now? 
Nick Van As
 
1430 Session 4
MDT: Liver Cancer - Chair: Dhakshina Vijayanand
Case presentation: Ashley Thorpe and Dharmadev Trivedi
Expert panel: David Kay, Nagappan Kumar, Rebecca Murihead, Adel Samson, Shishir Shetty
 
1530 Session 5
MDT: Pancreatic Cancer - Chair: Pavan Najran
Case presentation: Ben Pickwell-Smith and Ibrahim Rajput
Expert panel: Ali Arshad, James Good, Adel Samson, Tze Min Wah
 
1630 Closing Session Alison Young  
1645 Meeting Close & Refreshments  

 

With thanks to our sponsors*:

We are working with you to change the fight against cancer. Our best-in-class portfolio enables personalised interventional strategies – innovative solutions that are supported by robust evidence and unparalleled educational partnership.
 

Founded in 2009, Clovis Oncology is a commercial stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.

Development Programs Are Focused on Providing the Right Drug, to the Right Patient at the Right Time.

Clovis’ product development programs generally target specific subsets of cancer, and the Company seeks to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, Clovis has the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths. Clovis believes this approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.

At Eisai, everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational team working across a global network of R&D facilities, manufacturing sites and marketing subsidiaries.  

Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in a variety of therapeutic areas in which a high unmet medical need remains, including oncology and neurology.

Our mission is clear; we strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy in everything we do.

Guerbet is a worldwide leader in medical imaging that has been supporting healthcare professionals since 1926. Guerbet offers a wide range of pharmaceutical products, medical devices, software and services for diagnostic and interventional imaging to improve the diagnosis and treatment of patients. A pioneer through more than 90 years in the field of contrast media with over 2,600 colleagues globally. Guerbet is continuously innovating with 10% of revenue dedicated to research and development across four centres in France, Israel and the United States.

HistoSonics is developing a non-invasive platform and novel sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify targeted tissues at the cellular level. Utilizing advanced on-board imaging to target and personalize its therapy, histotripsy uses rapidly expanding and collapsing micro-bubbles to destroy targeted tissues, avoiding ionizing radiation, heat damage from thermal modalities, and incisions or needles from traditional treatments. Our mission and passion are to advance the novel science of histotripsy and its potential benefits, bringing meaningful and transformational change to physicians and their patients.

At IGEA we study the clinical application of physical stimuli to biological systems. IGEA is the leading company for Electrochemotherapy, a minimally invasive treatment combining a low dose of a chemotherapy drug and an electrical pulse (electroporation) applied directly to the cancer cells using specific multiple needle or individual needle electrodes. Our mission is to improve patients’ Quality of Life by developing and producing innovative, effective and safe therapeutic systems for clinical practice. Cliniporator® and Cliniporator® VITAE are the most advanced electroporation technologies for the treatment of tumour nodules located to the skin, subcutaneous tissue, parenchyma and bone.

At Ipsen, our licensed medicines and R&D cover a range of therapeutic areas. However, all are focused on curing disease and relieving suffering, hoping to bring real value to the healthcare community. Ipsen is committed to developing new treatments with the ability to improve and extend lives of those affected. Ipsen’s work in oncology currently focuses on several cancer types (including RCC, HCC, NET and prostate cancer) looking at where we can add benefit along every step of the treatment pathway and use targeted therapies to address conditions with high unmet needs.

The NEUWAVE™ Microwave Ablation System, now a part of the Ethicon™ portfolio of products, is the first intelligent ablation system and the only system that has it all. The versatile probe portfolio with multi-probe synchronized energy delivery allows physicians to tailor ablations with 1, 2 or 3 probes. In addition, the 17-gauge NEUWAVE™ PR probe is the only probe available with distal energy control to help protect non-target tissue. The unique computer-controlled system now includes Ablation Confirmation™ software, offering the only integrated in-procedure confirmation to help confirm probe placement and evaluate the technical success of your procedure. Build your ablation program with the first intelligent ablation system and the only system that has it all.

Lilly is a global healthcare leader uniting caring with discovery to deliver innovative medicines. Whether it's treating rare tumour types, leveraging precision medicine or discovering new ways to advance existing treatments, we're dedicated to making greater differences in lives of people living with cancer. 

Our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.

Sirtex Medical is a global healthcare business with offices in the US, Australia, Germany and Singapore, working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy called SIR-Spheres® Y-90 resin microspheres. SIR-Spheres® Y-90 resin microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy. Learn more about Sirtex in our interactive virtual booth.

Terumo Interventional Systems provide a wide choice of products in our Interventional Oncology portfolio from Access with our extensive range of Progreat microcatheters which allow you to navigate distally and embolise reliably. Terumo’s coaxial system enables fast and smooth procedures with minimal preparation.  Our therapeutic options include HydroPearl & LifePearl for TACE procedure, Combination Therapy with LifePearl & TATO ablation. Radioembolisation is available with Quirem Scout & QuiremSpheres for SIRT treatment. We support BTACE with our innovative Occlusafe Microballoon Intervention – Terumo has the solution.  Terumo’s Learning Edge workshops allow clinicians to expand their range of procedures and we also offer Lunch & Learn sessions for you MDT teams.

UK Medical is a Sheffield based SME, we supply a range of interventional medical devices to the NHS and the private healthcare sector. We select proven, clinically effective devices that are not only cost effective, but also improve patient outcomes.

Visit our website: ukmedical.com
Email us: [email protected]
Tel: +44 (0) 114 268 8880

At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 70 years, we have developed, built, and delivered innovative cancer care technologies and interventional solutions for our clinical partners around the globe to help them treat millions of patients each year. Our 11,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit www.Varian.com and follow @VarianMedSys on Twitter.

*none of whom have had an input into the meeting agenda or content.

 

ACP Trainees Weekend 2021
Saturday 16 October - Sunday 17 October 2021

The workshop is followed by the annual ACP trainees’ weekend, unfortunately cancelled in 2020.  It is an opportunity for medical oncology trainees from around the UK to meet and is the only trainee-dedicated event of its kind.  We are really pleased to be able to hold this event in a face-to-face format.  The educational content includes focussed sessions on geriatric oncology and cancer survivorship, in addition to a well needed session on wellbeing and resilience.  With educational opportunities heavily impacted by COVID-19, we hope that many trainees are able to join this event, and we particularly welcome the new trainees just embarking on their medical oncology training.

Speakers: Click here to download details.

Programme: Click here to download the programme.

 

Programme

Saturday 16 October 2021

0915 - 0950 Registration with coffee  
0950 - 1000 Welcome and introduction
Dr Daniel Hughes, Dr Alison Berner
1000 - 1030 An introduction to OncoGeriatrics
Dr Nicolo Battisti, The Royal Marsden NHS Foundation Trust and President-Elect SIOG
1030 - 1100 Frailty assessment and oncology treatment in older adults with cancer
Dr Fabio Gomes, The Christie NHS Foundation Trust
1100 – 1120 COFFEE  
1120 - 1230 Workshop 1: Your Personal Wellbeing – Some Practical Tips
Dr Claire Hardy, Senior Lecturer, Lancaster University
Workshop 2: Optimisation of the older patient with cancer. An MDT approach
Dr Nicolo Battisti, Dr Fabio Gomes, Jennie Blake and Jenna Morgan
1230 – 1330 NETWORKING LUNCH  
1330 - 1355 Surgical oncology in older adults
Dr Jenna Morgan, Sheffield
1355 - 1440 Research presentations and awards
McElwain Prize Presentations (Clinical + Translational)
James Clark – (Clinical) & Sophia Wong (Translational)
ACP President’s Award presentation
Carina Owen
1440 - 1500 COFFEE  
1500 - 1545 Medical Oncology SCE review
Dr Daniel Hughes, Dr Anna Olsson-Brown
1545 - 1630 Training updates:
- Medical oncology curriculum 2021
- Closer working update
- Other matters
ACP trainees’ committee, Dr Jackie Newby
1830 - 1930 Drinks Reception (Duchess Suite)  
1930 - 0000 Dinner & Dance (Ballroom Suite)
After-dinner speaker: Professor Jane Maher & Award Presentations

Sunday 17 October 2021

0930 - 1000 Registration with coffee  
1000 - 1030 Cancer survivorship
Prof Jane Maher
 
1030 - 1100 Survivorship for a TYA population
Dr Lucy Gossage
1100 - 1120 REFRESHMENT BREAK  
1120 - 1150 Cardio-oncology: an overview and implications for survivorship
Dr Charlotte Manisty, Bart’s Heart Centre and UCL
1150 - 1215 Diabetes management in patients on SACT: national guidelines
Dr Nalinie Joharatnam-Hogan, SpR Medical Oncology, The Royal Marsden NHS Foundation Trust, UK Chemotherapy Board
1215 - 1230 Close of session. Summary and feedback.
1230 LUNCH  

 

Venue & Accommodation

The Workshop and Trainees Weekend will take place at the Mercure Bristol Grand Hotel.

Complimentary Friday and Saturday night accommodation is offered to trainees and can be booked via the registration site.

If you wish to stay additional nights at the conference hotel, please click here to book directly.